Kyprolis and Metabolic encephalopathy - a phase IV clinical study of FDA data

Summary:

Metabolic encephalopathy is reported as a side effect among people who take Kyprolis (carfilzomib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Revlimid, and have Nephrogenic anaemia.

The phase IV clinical study analyzes which people have Metabolic encephalopathy when taking Kyprolis. It is created by eHealthMe based on reports of 15,068 people who have side effects when taking Kyprolis from the FDA, and is updated regularly.

What is Kyprolis?

Kyprolis has active ingredients of carfilzomib. It is often used in multiple myeloma. eHealthMe is studying from 15,080 Kyprolis users. Check the latest studies of Kyprolis.

What is Metabolic encephalopathy?

Metabolic encephalopathy (disorder or disease of the brain due to the body's disability to use energy) is found to be associated with 550 drugs and 589 conditions by eHealthMe. Check the latest studies of Metabolic encephalopathy.

On Jul, 26, 2026

15,068 people reported to have side effects when taking Kyprolis.
Among them, 15 people (0.1%) have Metabolic encephalopathy.

Could Kyprolis cause Metabolic encephalopathy?

Among these 15 people:

How long have people been on Kyprolis when they have Metabolic encephalopathy? *

What is the gender of people who have Metabolic encephalopathy when taking Kyprolis? *

female: 70 %
male: 30 %

What is the age of people who have Metabolic encephalopathy when taking Kyprolis? *

What are other drugs people take besides Kyprolis? *

Revlimid: 7 people, 46.67%
Velcade: 5 people, 33.33%
Pomalyst: 3 people, 20.00%
Decadron: 3 people, 20.00%
Levaquin: 2 people, 13.33%
Aranesp: 2 people, 13.33%
Zofran: 1 person, 6.67%
Rivaroxaban: 1 person, 6.67%
Promethazine: 1 person, 6.67%
Piperacillin And Tazobactam: 1 person, 6.67%

What are other side effects people have besides Metabolic encephalopathy? *

Subdural Haematoma (blood collects between the skull and the surface of the brain): 4 people, 26.67%
Upper Respiratory Tract Infection: 3 people, 20.00%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 3 people, 20.00%
Urinary Tract Infection: 2 people, 13.33%
Oedema (fluid collection in tissue): 2 people, 13.33%
Encephalopathy (functioning of the brain is affected by some agent or condition): 2 people, 13.33%
Fatigue (feeling of tiredness): 2 people, 13.33%
Fluid Overload (too much fluid in the blood): 2 people, 13.33%
Bundle Branch Block Right (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the right ventricle): 2 people, 13.33%
Hyperkalemia (damage to or disease of the kidney): 2 people, 13.33%

What are the existing conditions these people have? *

Upper Respiratory Tract Infection: 2 people, 13.33%
Nephrogenic Anaemia (anaemia due to kidney disease): 2 people, 13.33%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 6.67%
Pain: 1 person, 6.67%
Nausea And Vomiting: 1 person, 6.67%
Nausea (feeling of having an urge to vomit): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Kyprolis and have Metabolic encephalopathy?

- Check whether Metabolic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kyprolis:

Kyprolis (15,080 reports)

Browse all side effects of Kyprolis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metabolic encephalopathy:

Metabolic encephalopathy (550 drugs)

Browse all the conditions that are associated with Metabolic encephalopathy:

Metabolic encephalopathy (589 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carfilzomib (the active ingredients of Kyprolis) and Kyprolis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.